Skip to main content
NCBI home page
Heart logoLink to Heart
. 2001 Feb;85(2):171–178. doi: 10.1136/heart.85.2.171

Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: a randomised controlled study

T Levy 1, S Walker 1, M Mason 1, P Spurrell 1, S Rex 1, S Brant 1, V Paul 1
PMCID: PMC1729623  PMID: 11156667

Abstract

OBJECTIVE—To determine the importance of rhythm regulation or rate control in patients with permanent atrial fibrillation (AF) and normal left ventricular function.
PATIENTS AND INTERVENTIONS—Thirty six patients with a mixed fast and slow ventricular response rate to their AF were randomised to either His bundle ablation (HBA) and VVIR pacemaker (HBA group) or VVI pacemaker and atrioventricular modifying drugs (Med group). Outcomes assessed at one, three, six, and 12 months included exercise duration and quality of life.
RESULTS—Exercise duration significantly improved from baseline in both groups. There was no difference in outcome between the groups (Med +40% v HBA +20%, p = NS). The heart rate profile on exercise was similarly slowed in both groups compared to baseline. Quality of life significantly improved in both treatment arms for the modified Karolinska questionnaire (KQ) (Med +50% v HBA +50%, p = NS) and the Nottingham health profile (NHP) (Med +40% v HBA +20%, p = NS). However, for the individual symptom scores of each questionnaire more were improved in the Med group (KQ-Med 6 improved v HBA 4, NHP-Med 3 v HBA 1). Left ventricular function was equally preserved by both treatments during follow up.
CONCLUSION—In these patients control of ventricular response rate with either HBA + VVIR pacemaker or atrioventricular modifying drugs + VVI pacemaker will lead to a significant improvement in exercise duration and quality of life. Rhythm regulation by HBA did not confer additional benefit, suggesting rate control alone is necessary for the successful symptomatic treatment of these patients in permanent AF.


Keywords: ablation; atrial fibrillation; pacemaker; atrioventricular modifying drugs

Full Text

The Full Text of this article is available as a PDF (175.4 KB).

Figure 1  .

Figure 1  

Open in a new tab

Exercise duration in seconds on treadmill testing for both groups (Med, medical; HBA, ablation) at baseline and at all follow ups. Intra-group comparison for Med and HBA group showed a significant improvement compared to baseline at all follow ups. Inter-group comparison (Med v HBA) showed no significant difference at any time.

Figure 2  .

Figure 2  

Open in a new tab

Example of heart rate profile on exercise in both groups for baseline (Med B, medical group baseline; HBA B, ablation group baseline) and at six months follow up (Med 6, medical group at six months; HBA 6, ablation group at six months). Profile shown at one minute intervals for the first three minutes. Intra-group comparison (Med B v Med 6 and HBA B v HBA 6) showed a significant slowing in heart rate at all time intervals for both groups except the resting heart rate in the medical group at six months that had not significantly changed from baseline. Inter-group comparison at baseline (Med B v HBA B) showed no significant difference in heart rate profile for any of the time intervals, while at six months (Med 6 v HBA 6) the only significant difference was in the resting heart rate (p = 0.015).

Figure 3  .

Figure 3  

Open in a new tab

Example of part 2 NHP results at baseline and six months showing the percentage of patients answering yes to each question. There was no significant difference either intra-group or inter-group. Med B, medical group baseline; Med 6, medical group at six months; HBA B, ablation group baseline; HBA 6, ablation group at 6 months; J, occupation; H, ability to perform jobs around the home; SL, social life; HL, home relationships; SE, sex life; IH, interest/hobbies; H, holidays.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atwood J. E., Sullivan M., Forbes S., Myers J., Pewen W., Olson H. G., Froelicher V. F. Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol. 1987 Aug;10(2):314–320. doi: 10.1016/s0735-1097(87)80013-x. [DOI] [PubMed] [Google Scholar]
  2. Brignole M., Gianfranchi L., Menozzi C., Bottoni N., Bollini R., Lolli G., Oddone D., Gaggioli G. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol. 1994 Aug 1;74(3):242–246. doi: 10.1016/0002-9149(94)90364-6. [DOI] [PubMed] [Google Scholar]
  3. Brignole M., Menozzi C., Gianfranchi L., Musso G., Mureddu R., Bottoni N., Lolli G. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation. 1998 Sep 8;98(10):953–960. doi: 10.1161/01.cir.98.10.953. [DOI] [PubMed] [Google Scholar]
  4. Buys E. M., van Hemel N. M., Kelder J. C., Ascoop C. A., van Dessel P. F., Bakema L., Kingma J. H. Exercise capacity after His bundle ablation and rate response ventricular pacing for drug refractory chronic atrial fibrillation. Heart. 1997 Mar;77(3):238–241. doi: 10.1136/hrt.77.3.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Caine N., Harrison S. C., Sharples L. D., Wallwork J. Prospective study of quality of life before and after coronary artery bypass grafting. BMJ. 1991 Mar 2;302(6775):511–516. doi: 10.1136/bmj.302.6775.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cannan C. R., Higano S. T., Holmes D. R., Jr Pacemaker induced mitral regurgitation: an alternative form of pacemaker syndrome. Pacing Clin Electrophysiol. 1997 Mar;20(3 Pt 1):735–738. doi: 10.1111/j.1540-8159.1997.tb03895.x. [DOI] [PubMed] [Google Scholar]
  7. Clark D. M., Plumb V. J., Epstein A. E., Kay G. N. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997 Oct;30(4):1039–1045. doi: 10.1016/s0735-1097(97)00254-4. [DOI] [PubMed] [Google Scholar]
  8. Daoud E. G., Weiss R., Bahu M., Knight B. P., Bogun F., Goyal R., Harvey M., Strickberger S. A., Man K. C., Morady F. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol. 1996 Dec 15;78(12):1433–1436. doi: 10.1016/s0002-9149(97)89297-1. [DOI] [PubMed] [Google Scholar]
  9. Edner M., Caidahl K., Bergfeldt L., Darpö B., Edvardsson N., Rosenqvist M. Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Br Heart J. 1995 Sep;74(3):261–267. doi: 10.1136/hrt.74.3.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fitzpatrick A. P., Kourouyan H. D., Siu A., Lee R. J., Lesh M. D., Epstein L. M., Griffin J. C., Scheinman M. M. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J. 1996 Mar;131(3):499–507. doi: 10.1016/s0002-8703(96)90528-1. [DOI] [PubMed] [Google Scholar]
  11. Heinz G., Siostrzonek P., Kreiner G., Gössinger H. Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol. 1992 Feb 15;69(5):489–492. doi: 10.1016/0002-9149(92)90991-7. [DOI] [PubMed] [Google Scholar]
  12. James M. A., Channer K. S., Papouchado M., Rees J. R. Improved control of atrial fibrillation with combined pindolol and digoxin therapy. Eur Heart J. 1989 Jan;10(1):83–90. doi: 10.1093/oxfordjournals.eurheartj.a059386. [DOI] [PubMed] [Google Scholar]
  13. Le Tourneau T., Klug D., Lacroix D. Mitral valve replacement for pacing-induced severe mitral regurgitation after radiofrequency ablation of the atrioventricular junction. Heart. 1996 Nov;76(5):457–457. doi: 10.1136/hrt.76.5.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lewis R. V., Irvine N., McDevitt D. G. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J. 1988 Jul;9(7):777–781. doi: 10.1093/eurheartj/9.7.777. [DOI] [PubMed] [Google Scholar]
  15. Lewis R. V., Laing E., Moreland T. A., Service E., McDevitt D. G. A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J. 1988 Mar;9(3):279–283. doi: 10.1093/oxfordjournals.eurheartj.a062497. [DOI] [PubMed] [Google Scholar]
  16. Lewis R. V., McMurray J., McDevitt D. G. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol. 1989 Jan;13(1):1–6. doi: 10.1097/00005344-198901000-00002. [DOI] [PubMed] [Google Scholar]
  17. Linde C. How to evaluate quality-of-life in pacemaker patients: problems and pitfalls. Pacing Clin Electrophysiol. 1996 Apr;19(4 Pt 1):391–397. doi: 10.1111/j.1540-8159.1996.tb06508.x. [DOI] [PubMed] [Google Scholar]
  18. Lundström T., Rydén L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol. 1990 Jul;16(1):86–90. doi: 10.1016/0735-1097(90)90461-w. [DOI] [PubMed] [Google Scholar]
  19. Matsuda M., Matsuda Y., Yamagishi T., Takahashi T., Haraguchi M., Tada T., Kusukawa R. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovasc Res. 1991 Jun;25(6):453–457. doi: 10.1093/cvr/25.6.453. [DOI] [PubMed] [Google Scholar]
  20. Naito M., David D., Michelson E. L., Schaffenburg M., Dreifus L. S. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J. 1983 Aug;106(2):284–291. doi: 10.1016/0002-8703(83)90194-1. [DOI] [PubMed] [Google Scholar]
  21. Natale A., Zimerman L., Tomassoni G., Kearney M., Kent V., Brandon M. J., Newby K. Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response. Am J Cardiol. 1996 Dec 15;78(12):1431–1433. doi: 10.1016/s0002-9149(97)89296-x. [DOI] [PubMed] [Google Scholar]
  22. Natale A., Zimerman L., Tomassoni G., Newby K., Leonelli F., Fanelli R., Beheiry S., Pisano E. AV node ablation and pacemaker implantation after withdrawal of effective rate-control medications for chronic atrial fibrillation: effect on quality of life and exercise performance. Pacing Clin Electrophysiol. 1999 Nov;22(11):1634–1639. doi: 10.1111/j.1540-8159.1999.tb00383.x. [DOI] [PubMed] [Google Scholar]
  23. Pocock S. J., Henderson R. A., Seed P., Treasure T., Hampton J. R. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Circulation. 1996 Jul 15;94(2):135–142. doi: 10.1161/01.cir.94.2.135. [DOI] [PubMed] [Google Scholar]
  24. Rodriguez L. M., Smeets J. L., Xie B., de Chillou C., Cheriex E., Pieters F., Metzger J., den Dulk K., Wellens H. J. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol. 1993 Nov 15;72(15):1137–1141. doi: 10.1016/0002-9149(93)90982-i. [DOI] [PubMed] [Google Scholar]
  25. Rosenquvist M., Lee M. A., Moulinier L., Springer M. J., Abbott J. A., Wu J., Langberg J. J., Griffin J. C., Scheinman M. M. Long-term follow-up of patients after transcatheter direct current ablation of the atrioventricular junction. J Am Coll Cardiol. 1990 Nov;16(6):1467–1474. doi: 10.1016/0735-1097(90)90394-5. [DOI] [PubMed] [Google Scholar]
  26. Singh S., Saini R. K., DiMarco J., Kluger J., Gold R., Chen Y. W. Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group. Am J Cardiol. 1991 Nov 1;68(11):1227–1230. doi: 10.1016/0002-9149(91)90200-5. [DOI] [PubMed] [Google Scholar]
  27. Tse H. F., Lau C. P. Long-term effect of right ventricular pacing on myocardial perfusion and function. J Am Coll Cardiol. 1997 Mar 15;29(4):744–749. doi: 10.1016/s0735-1097(96)00586-4. [DOI] [PubMed] [Google Scholar]
  28. Twidale N., Sutton K., Bartlett L., Dooley A., Winstanley S., Heddle W., Hassam R., Koutsounis H. Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias. Pacing Clin Electrophysiol. 1993 Jun;16(6):1275–1284. doi: 10.1111/j.1540-8159.1993.tb01714.x. [DOI] [PubMed] [Google Scholar]
  29. Vanderheyden M., Goethals M., Anguera I., Nellens P., Andries E., Brugada J., Brugada P. Hemodynamic deterioration following radiofrequency ablation of the atrioventricular conduction system. Pacing Clin Electrophysiol. 1997 Oct;20(10 Pt 1):2422–2428. doi: 10.1111/j.1540-8159.1997.tb06081.x. [DOI] [PubMed] [Google Scholar]
  30. Wong C. K., Lau C. P., Leung W. H., Cheng C. H. Usefulness of labetalol in chronic atrial fibrillation. Am J Cardiol. 1990 Nov 15;66(17):1212–1215. doi: 10.1016/0002-9149(90)91102-c. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES